Brainstorm Cell Therapeutics, Inc.

NASDAQ:BCLI  
1.66
+0.01 (+0.61%)
6:35:41 PM EDT: $1.64 -0.02 (-1.21%)
Earnings Announcements

Brainstorm Cell Therapeutics Announces Q3 2022 Financial Results

Published: 11/14/2022 12:12 GMT
Brainstorm Cell Therapeutics, Inc. (BCLI) - Brainstorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update.
Brainstorm Cell Therapeutics Inc - Qtrly Loss per Share $0.19.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.15

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.